Journal of Immunology Research / 2013 / Article / Tab 2

Review Article

Interleukin-17: A Promoter in Colorectal Cancer Progression

Table 2

Expression of IL-17 in CRC patients.

Sample typeSample sizeFindingsReferences

Serum and tissue74 CRC tissues and paired normal mucosa, 61 CRC serum samples, and 78 healthy controlsNo significant difference is observed. [59]

Serum and tissue59 CRC tissues, 40 CRC serum samples, and 37 healthy controlsIL-17 acts as a valuable tumor marker in CRC patients.[56]

Tissue12 CRC patientsHypoxia induce the expression of IL-17 in Foxp3+ Tregs, which drive cancer cells to be cancer-initiating cells.[51]

Tissue125 CRC tissues and 3 normal tissuesIL-17 gene expression level is higher in tumor tissues compared to normal mucosa.[60]

Tissue52 CRC patientsIL-17 expression is negatively correlated with OS of CRC patients.[52]

Tissue22 CRC patientsTumor-infiltrating Foxp3+ IL-17+ T cells suppress tumor-specificCD8+T cells response via IL-17.[49]

Serum and tissue 9 ulcerative colitis-associated CRC tissuesIL-17+ Foxp3+ CD4+ T cells are selectively accumulated in the colitis-associated CRC niche.[61]

Tissue50 colorectal adenomas tissues, 50 CRC tissues, and 15 healthy controlsIL-17 level is associated with the severity of dysplastic degree.[58]

Tissue23 CRC patientsTumor-infiltrating TH17 cells and Bv8-expressing neutrophils are associated with poor outcome in CRC.[50]

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.